RT Journal Article
SR Electronic
T1 Antibody responses to BNT162b2 vaccination in Japan: Monitoring vaccine efficacy by measuring IgG antibodies against the receptor binding domain of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.19.21260728
DO 10.1101/2021.07.19.21260728
A1 Hidetsugu Fujigaki
A1 Yasuko Yamamoto
A1 Takenao Koseki
A1 Sumi Banno
A1 Tatsuya Ando
A1 Hiroyasu Ito
A1 Takashi Fujita
A1 Hiroyuki Naruse
A1 Tadayoshi Hata
A1 Saya Moriyama
A1 Yoshimasa Takahashi
A1 Tadaki Suzuki
A1 Takahiro Murakami
A1 Yukihiro Yoshida
A1 Yo Yagura
A1 Takayoshi Oyamada
A1 Masao Takemura
A1 Masashi Kondo
A1 Mitsunaga Iwata
A1 Kuniaki Saito
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260728.abstract
AB BACKGROUND To fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), mass vaccination has begun in many countries. To investigate the usefulness of a serological assay to predict vaccine efficacy, we analyzed the levels of IgG, IgM, and IgA against the receptor binding domain (RBD) of SARS-CoV-2 in the sera from BNT162b2 vaccinated individuals in Japan.METHODS This study included 219 individuals who received two doses of BNT162b2. The levels of IgG, IgM, and IgA against RBD were measured by enzyme-linked immunosorbent assay before and after the first and second vaccination, respectively. The relationship between antibody levels and several factors including age, gender, and hypertension were analyzed. Virus-neutralizing activity in sera was measured to determine the correlation with the levels of antibodies. A chemiluminescent enzyme immunoassay (CLEIA) method to measure IgG against RBD was developed and validated for the clinical setting.RESULTS The levels of all antibody isotypes were increased after vaccination. Among them, RBD-IgG was dramatically increased after the second vaccination. The IgG levels in females were significantly higher than in males. There was a negative correlation between age and IgG levels in males. The IgG levels significantly correlated with the neutralizing activity. The CLEIA assay measuring IgG against RBD showed a reliable performance and a high correlation with neutralizing activity.CONCLUSIONS Monitoring of IgG against RBD is a powerful tool to predict the efficacy of SARS-CoV-2 vaccination and provides useful information in considering a personalized vaccination strategy for COVID-19.Competing Interest StatementT. Murakami, Y. Yoshida, and Y. Yagura are employees of FUJIFILM Wako Pure Chemical Corp. T. Oyamada is an employee of FUJIFILM Corp. The other authors have no financial conflicts of interest.Funding StatementThis study was supported by the Japan Agency for Medical Research and Development (JP19fk0108110, JP20fk0108534, and JP20he1122003) and the FUJIFILM Wako Pure Chemical Corp.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee for Clinical Research of the Center for Research Promotion and Support at Fujita Health University (authorization number HM20-526 and HM21-167). The study was carried out with accordance to Declaration of Helsinki. All participants provided written informed consent before undergoing any study procedure.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request due to privacy or other restrictionsSARS-CoV-2severe acute respiratory syndrome coronavirus 2COVID-19coronavirus disease 2019RBDreceptor binding domainCLEIAchemiluminescent enzyme immunoassaySspikeNnucleocapsidRBD-IgGIgG against RBDPBS-TPhosphate buffered saline containing 0.1% Tween 20MNTmicroneutralization test titre